Telmisartan ameliorates inflammatory responses in SHR-SR after tMCAO

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 10, 2014, Pages 2511-2519

  Sato, Kota ^a   Yamashita, Toru ^a   Kurata, Tomoko ^a   Fukui, Yusuke ^a   Hishikawa, Nozomi ^a   Deguchi, Kentaro ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Iba 1; Inflammatory response; MCP, 1; Spontaneously hypertensive rat; Telmisartan; TNF;

Indexed keywords

CALCIUM BINDING PROTEIN; IONIZED CALCIUM BINDING ADAPTER MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; AIF1 PROTEIN, RAT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; AUTACOID; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BRAIN CORTEX; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG MEGADOSE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; HYPERTENSION; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; INFLAMMATION; LOW DRUG DOSE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TRANSIENT ISCHEMIC ATTACK; ANIMAL; CEREBRAL ARTERY DISEASE; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; STROKE; TIME; TREATMENT OUTCOME;

AGE FACTORS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CALCIUM-BINDING PROTEINS; CEREBRAL CORTEX; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFARCTION, MIDDLE CEREBRAL ARTERY; INFLAMMATION MEDIATORS; MALE; MICROFILAMENT PROTEINS; RATS; RATS, INBRED SHR; STROKE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923251842     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2014.02.019     Document Type: Article

References (21)

1. Tsuchiya A, Nagotani S, Hayashi T, et al. Macrophage infiltration, lectin-like oxidized-LDL receptor-1, and monocyte chemoattractant protein-1 are reduced by chronic HMG-CoA reductase inhibition. Curr Neurovasc Res 2007; 4: 268-273.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
3. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 2009; 7: 97.
4. Kawai H, Deguchi S, Deguchi K, et al. Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat. Brain Res 2011; 1368: 317-323.
5. Gohlke P, Weiss S, Jansen A, et al. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 2001; 298: 62-70.
6. Maillard MP, Perregaux C, Centeno C, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002; 302: 1089-1095.
7. Dai Q, Xu M, Yao M, et al. AngiotensinAT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 2007; 152: 1042-1048.
8. Kubota M, Shimizu M, Sakai H, et al. Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Biochem Biophys Res Commun 2011; 410: 108-113.
9. Paton JF, Waki H. Is neurogenic hypertension related to vascular inflammation of the brainstem? Neurosci Biobehav Rev 2009; 33: 89-94.
10. Waki H, Gouraud SS, Maeda M, et al. Gene expression profiles of major cytokines in the nucleus tractus solitarii of the spontaneously hypertensive rat. Auton Neurosci 2008; 142: 40-44.
11. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 2011; 17: 796-808.
12. Hinojosa AE, Garcia-Bueno B, Leza JC, et al. CCL2/MCP- 1 modulation of microglial activation and proliferation. J Neuroinflammation 2011; 8: 77.
13. Stoll G, Jander S, Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol 1998; 56: 149-171.
14. Worthmann H, Tryc AB, Goldbecker A, et al. The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis (Basel, Switzerland) 2010; 30: 85-92.
15. Adibhatla RM, Hatcher JF. Secretory phospholipase A2 IIA is up-regulated by TNF-alpha and IL-1alpha/beta after transient focal cerebral ischemia in rat. Brain Res 2007; 1134: 199-205.
16. Sakurai-Yamashita Y, Shigematsu K, Yamashita K, et al. Expression of MCP-1 in the hippocampus of SHRSP with ischemia-related delayed neuronal death. Cell Mol Neurobiol 2006; 26: 823-831.
17. Heldmann U, Thored P, Claasen JH, et al. TNF-alpha antibody infusion impairs survival of stroke-generated neuroblasts in adult rat brain. Exp Neurol 2005; 196: 204-208.
18. Imayama I, Ichiki T, Inanaga K, et al. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 2006; 72: 184-190.
19. Fukui Y, Yamashita T, Kurata T, et al. Protective effect of telmisartan against progressive oxidative brain damage and synuclein phosphorylation in SHR-SR rats. J Stroke Cerebrovasc Dis 2014; 23: 1545-1553.
20. Sato K, Yamashita T, Kurata T, et al. Telmisartan reduces progressive oxidative stress and phosphorylated a-synuclein accumulation in SHR-SR rats after tMCAO. J Stroke Cerebrovasc Dis 2014; 23: 1554-1563.
21. Xu L, Liu Y. Administration of telmisartan reduced systolic blood pressure and oxidative stress probably through the activation of PI3K/Akt/eNOS pathway and NO release in spontaneously hypertensive rats. Physiol Res 2013; 62: 351-359.